News Daily News Nearly 150 Million US Adults Eligible for CKM Syndrome Meds Caitlin E. Cox February 02, 2026
News Daily News Previewing 30-Year ASCVD Risk May Open Door to Earlier Treatment Yael L. Maxwell January 21, 2026
News Daily News SURPASS-CVOT Published: Large Trial Confirms CVD Efficacy of Tirzepatide Michael O'Riordan December 18, 2025
News Daily News Patients With Obesity Get Biggest Benefit from Evolocumab: FOURIER Michael O'Riordan December 12, 2025
News Daily News Semaglutide’s CV Effects Only Partially Tied to Weight Loss: SELECT Analysis Yael L. Maxwell October 24, 2025
News Daily News High Aerobic Fitness Linked to Less Chronic Disease in Later Life Michael O'Riordan October 10, 2025
News Daily News Risk Factors Present in Nearly All Patients Who Develop CVD Michael O'Riordan October 02, 2025
News Daily News CVD Still the Leading Cause of Death and Disease Globally Michael O'Riordan September 24, 2025
News Daily News Better Outcomes and Lower Cost with Bariatric Surgery Over GLP-1s Michael O'Riordan September 18, 2025
News Daily News Lower-Calorie Mediterranean Diet Plus Exercise Boosts Diabetes Prevention Todd Neale August 25, 2025
News Daily News AI-Supported Coaching Shows Promise for Improving Glycemic Control L.A. McKeown August 25, 2025
News Daily News Prevention Must Be Prioritized in Heart Failure Care: HFSA/ASPC Yael L. Maxwell August 18, 2025
News Daily News Glipizide, Commonly Used Sulfonylurea, Linked to Greater CV Risks Michael O'Riordan August 01, 2025
News Daily News Tirzepatide Matches Dulaglutide in Large CV Outcomes Trial: SURPASS-CVOT Michael O'Riordan July 31, 2025